

Robyn T Domsic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3719522/publications.pdf>

Version: 2024-02-01

53
papers

2,103
citations

218677
26
h-index

243625
44
g-index

53
all docs

53
docs citations

53
times ranked

2195
citing authors

#	ARTICLE	IF	CITATIONS
1	Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 104-109.	0.9	201
2	Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2020, 72, 125-136.	5.6	163
3	A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2012, 64, 2986-2994.	6.7	134
4	Gastrointestinal Manifestations of Systemic Sclerosis. <i>Digestive Diseases and Sciences</i> , 2008, 53, 1163-1174.	2.3	108
5	Anti-U11/U12 RNP antibodies in systemic sclerosis: A new serologic marker associated with pulmonary fibrosis. <i>Arthritis and Rheumatism</i> , 2009, 61, 958-965.	6.7	105
6	Myofibroblast transcriptome indicates SFRP2hi fibroblast progenitors in systemic sclerosis skin. <i>Nature Communications</i> , 2021, 12, 4384.	12.8	101
7	Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 379-386.	0.9	97
8	Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 209-221.	5.6	88
9	Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 55-62.	3.4	69
10	Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1350-1360.	5.6	67
11	Scleroderma. <i>Current Opinion in Rheumatology</i> , 2014, 26, 646-652.	4.3	59
12	Skin-Resident Effector Memory CD8+CD28- T Cells Exhibit a Profibrotic Phenotype in Patients with Systemic Sclerosis. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1042-1050.	0.7	54
13	Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2018, 70, 1373-1384.	3.4	54
14	HLA and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 552-562.	7.1	52
15	Anti-PM-Scl antibody in patients with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S12-6.	0.8	45
16	A Proteome-Derived Longitudinal Pharmacodynamic Biomarker for Diffuse Systemic Sclerosis Skin. <i>Journal of Investigative Dermatology</i> , 2017, 137, 62-70.	0.7	44
17	Significance of Palpable Tendon Friction Rubs in Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2013, 65, 1385-1389.	3.4	43
18	Expansion of Fcγ3 Receptor-Positive Macrophages, Ficolin 1-Positive Monocyte-Derived Dendritic Cells, and Plasmacytoid Dendritic Cells Associated With Severe Skin Disease in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2022, 74, 329-341.	5.6	38

#	ARTICLE	IF	CITATIONS
19	Derivation and Validation of a Prediction Rule for Two-Year Mortality in Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2014, 66, 1616-1624.	5.6	37
20	Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults With Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1892-1896.	5.6	36
21	Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC vascular working group report. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 249-252.	1.7	33
22	Single-cell transcriptome analysis identifies skin-specific T-cell responses in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1453-1460.	0.9	32
23	Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study. <i>Journal of Rheumatology</i> , 2018, 45, 405-410.	2.0	31
24	Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort. <i>Arthritis Research and Therapy</i> , 2021, 23, 170.	3.5	30
25	Treatment of early diffuse systemic sclerosis skin disease. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 166-71.	0.8	30
26	Derivation and External Validation of a Prediction Rule for Five-Year Mortality in Patients With Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2016, 68, 993-1003.	5.6	29
27	Anti-RNAP3 (U11/U12) Antibodies in Systemic Sclerosis in Patients With Moderate-to-Severe Gastrointestinal Dysmotility. <i>Arthritis Care and Research</i> , 2019, 71, 1164-1170.	3.4	28
28	Multicenter Qualitative Study Exploring the Patient Experience of Digital Ulcers in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2020, 72, 723-733.	3.4	25
29	A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101707.	3.3	22
30	A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers. <i>Arthritis Research and Therapy</i> , 2019, 21, 202.	3.5	21
31	Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , 2021, 73, 1005-1013.	5.6	21
32	Serum biomarker for diagnostic evaluation of pulmonary arterial hypertension in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2018, 20, 185.	3.5	19
33	Autoantibodies and Their Role in Scleroderma Clinical Care. <i>Current Treatment Options in Rheumatology</i> , 2016, 2, 239-251.	1.4	16
34	Patient Perceptions of the Raynaud's Condition Score Diary Provide Insight Into Its Performance in Clinical Trials of Raynaud's Phenomenon: Comment on the Article by Denton et al. <i>Arthritis and Rheumatology</i> , 2018, 70, 973-974.	5.6	16
35	Reliability and Validity of the Tender and Swollen Joint Counts and the Modified Rodnan Skin Score in Early Diffuse Cutaneous Systemic Sclerosis: Analysis from the Prospective Registry of Early Systemic Sclerosis Cohort. <i>Journal of Rheumatology</i> , 2017, 44, 791-794.	2.0	14
36	Pulmonary Arterial Hypertension In Systemic Sclerosis: Challenges In Diagnosis, Screening And Treatment. <i>Open Access Rheumatology: Research and Reviews</i> , 2019, Volume 11, 323-333.	1.6	14

#	ARTICLE	IF	CITATIONS
37	An interim report of the Scleroderma Clinical Trials Consortium working groups. Journal of Scleroderma and Related Disorders, 2019, 4, 17-27.	1.7	13
38	Clinical Trial Design Issues in Systemic Sclerosis: an Update. Current Rheumatology Reports, 2016, 18, 38.	4.7	12
39	Defining the optimal disease duration of early diffuse systemic sclerosis for clinical trial design. Rheumatology, 2021, 60, 4662-4670.	1.9	12
40	Patient experiences of digital ulcer development and evolution in systemic sclerosis. Rheumatology, 2020, 59, 2156-2158.	1.9	11
41	Development of Pulmonary Hypertension in Over One-Third of Patients With Th/To Antibody-Positive Scleroderma in Long-Term Follow-Up. Arthritis and Rheumatology, 2022, 74, 1580-1587.	5.6	10
42	Development of a Neo-Epitope Specific Assay for Serological Assessment of Type VII Collagen Turnover and Its Relevance in Fibroproliferative Disorders. Assay and Drug Development Technologies, 2018, 16, 123-131.	1.2	9
43	<scp>Adipose-Derived</scp> Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial. Arthritis and Rheumatology, 2022, 74, 1399-1408.	5.6	9
44	Localized scleroderma and regional inflammatory myopathy. Neuromuscular Disorders, 2014, 24, 425-430.	0.6	8
45	Cardiac metabolomics and autopsy in a patient with early diffuse systemic sclerosis presenting with dyspnea: a case report. Journal of Medical Case Reports, 2015, 9, 136.	0.8	7
46	Patient participation in patient-reported outcome instrument development in systemic sclerosis. Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 184-192.	0.8	7
47	Prevention of cardiovascular disease in patients with rheumatic diseases. Best Practice and Research in Clinical Rheumatology, 2006, 20, 741-756.	3.3	6
48	Disease Subsets in Clinical Practice. , 2012, , 45-52.		6
49	A pilot study of dimethyl fumarate in pulmonary arterial hypertension associated with systemic sclerosis. Journal of Scleroderma and Related Disorders, 2021, 6, 242-246.	1.7	5
50	A genomic meta-analysis of clinical variables and their association with intrinsic molecular subsets in systemic sclerosis. Rheumatology, 0, , .	1.9	5
51	Disease Subsets in Clinical Practice. , 2017, , 39-48.		4
52	ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part III: Pharmacology, medical and surgical management of post-transplant extrapulmonary conditions statements. Journal of Heart and Lung Transplantation, 2021, 40, 1279-1300.	0.6	3
53	Reply. Arthritis and Rheumatology, 2021, 73, 716-717.	5.6	0